Retrovirally induced CTL degranulation mediated by IL-15 expression and infection of mononuclear phagocytes in patients with HTLV-I associated neurologic disease

Blood

Volumn 112, Issue 6, 2008, Pages 2400-2410

  Enose Akahata, Yoshimi ^a   Oh, Unsong ^a   Grant, Christian ^a   Jacobson, Steven ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; GAMMA INTERFERON; HLA A ANTIGEN; INTERLEUKIN 15; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; VIRUS ANTIGEN; VIRUS DNA;

ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DEGRANULATION; DISEASE ASSOCIATION; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS INFECTION; INTERFERON PRODUCTION; MONONUCLEAR PHAGOCYTE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RETROVIRUS; SPASTIC PARAPLEGIA; VIRUS EXPRESSION; COCULTURE; GENE EXPRESSION; GENETICS; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNOLOGY; PATHOGENICITY; PHAGOCYTE; VIROLOGY;

ANTIGENS, CD14; CD8-POSITIVE T-LYMPHOCYTES; CELL DEGRANULATION; COCULTURE TECHNIQUES; GENE EXPRESSION; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; INTERFERON TYPE II; INTERLEUKIN-15; PARAPARESIS, TROPICAL SPASTIC; PHAGOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 55249083122     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-02-138529     Document Type: Article

References (73)

1. Verdonck K, Gonzalez E, Van Dooren S. Vandamrne AM, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis. 2007;7: 266-281.
2. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A. 1980;77: 7415-7419.
3. Gessain A, Barin F, Vernant JC, et al. Antibodies to human T-lymphotropic virus type-l in patients with tropical spastic paraparesis. Lancet. 1985;2: 407-410.
4. Osame M, Usuku K, Izumo S, et al. HTLV-I associated myelopathy, a new clinical entity. Lancet. 1986:1:1031-1032.
5. Itoyama Y, Minato S, Kira J. et al. Spontaneous proliferation of peripheral blood lymphocytes increased in patients with HTLV-l-associated myelopathy. Neurology. 1988;38:1302-1307.
6. Jacobson S. Shida H, McFarlin DE, Fauci AS, Koenig S. Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature. 1990;348:245-248.
7. Hanon E, Goon P, Taylor GP, et al. High production of interferon gamma but not interleukin-2 by human T-lymphotropic virus type l-infected peripheral blood mononuclear cells. Blood. 2001:98: 721-726.
8. Kubota R, Kawanishi T Matsubara H, Manns A, Jacobson S. HTLV-I specific IFN-gamma+ GD8+ lymphocytes correlate with the proviral load in peripheral blood of infected individuals. J Neuroimmunol. 2000:102:208-215.
9. Yamano Y, Nagai M, Brennan M, et al. Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRN Awith proviral DNA Ioad, virusspecific CD8(+) T cells, and disease severity in HTLV-1-associated myelopathy (HAM/TSP). Blood. 2002;99:88-94.
10. Jeffery KJ, Siddiqui AA, Bunce M, et al. The influence of HLA class I alleles and heterozygosity on the outcome of human T cell lymphotropic virus type I infection. J Immunol. 2000;165:7278-7284.
11. Vine AM, Witkover AD, Lloyd AL, et al. Polygenic control of human T lymphotropic virus type I (HTLV-I) provirus load and the risk of HTLV-lassociated myelopathy/tropical spastic paraparesis. J Infect Dis. 2002;186:932-939.
12. Kodama D, Saito M, Matsumoto W, et al. Longer dinucleotide repeat polymorphism in matrix metalloproteinase-9 (MMP-9) gene promoter which correlates with higher HTLV-I Tax mediated transcriptional activity influences the risk of HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP). J Neuroimmunol. 2004;156:188-194.
13. SabouriAH, Saito M, Lloyd AL, etal. Polymorphism in the interleukin-10 promoter affects both provirus load and the risk of human T lymphotropic virus type l-associated myelopathy/tropical spastic paraparesis. J Infect Dis. 2004;190:1279-1285.
14. Bangham CR, Osame M. Gellular immune response to HTLV-1. Oncogene. 2005;24:6035-6046.
15. Hoffman PM, Dhib-Jalbut S, Mikovits JA, etal. Human T-cell leukemia virus type I infection of monocytes and microglial cells in primary human cultures. Proc Natl Acad Sci U SA. 1992;89: 11784-11788.
16. KoralniklJ, Lemp JFJr, Gallo RC, Franchini G. In vitro infection of human macrophages by human T-cell leukemia/lymphotropic virus type I (HTLV-I). AIDS Res Hum Retroviruses. 1992;8:1845-1849.
17. Koyanagi Y, Itoyama Y, Nakamura N. etal. In vivo infection of human T-cell leukemia virus type I in non-Tcells. Virology. 1993;196:25-33.
18. Makino M, Shimokubo S, Wakamatsu SI, Izumo S. Baba M. The role of human T-lymphotropic virus type 1 (HTLV-1)-infected dendritic cells in the development of HTLV-1-associated myelopathy/tropical spastic paraparesis. J Virol. 1999;73: 4575-4581.
19. Hanon E, Stinchcombe JC, Saito M. etal. Fratricide among CD8(+) T lymphocytes naturally infected with human T cell lymphotropic virus type I. Immunity. 2000;13:657-664.
20. Nagai M, Brennan MB, Sakai JA, Mora GA, Jacobson S. CD8(+) T cells are an in vivo reservoir for human T-cell lymphotropic virus type I. Blood. 2001;98:1858-1861.
21. Richardson JH, Edwards AJ, Cruickshank JK, Rudge P, Dalgleish AG. In vivo cellular tropism of human T-cell leukemia virus type 1. J Virol. 1990; 64:5682-5687.
22. Uchiyama T. Adult T-cell leukemia. Blood Rev. 1988;2:232-238.
23. Yamano Y, Takenouchi N, Li HC, et al. Virusinduced dysfunction of CD4+CD25+ T cells in patients with HTLV-l-associated neuroimmunological disease. J Clin Invest. 2005;115:1361-1368.
24. Oh U, Yamano Y, Mora CA, etal. Interferonbetal a therapy in human T-lymphotropic virus type l-associated neurologic disease. Ann Neurol. 2005;57:526-534.
25. Hazenberg MD, Hamann D, Schuitemaker H, Miedema F. T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock. Nat Immunol. 2000;1:285-289.
26. Nagai M, Usuku K. MatsumotoW, etal. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol. 1998;4:586-593.
27. Nagai M, Yamano Y Brennan MB, Mora CA, Jacobson S. Increased HTLV-I proviral load and preferential expansion of HTLV-I Taxspecific CD8+ T cells in cerebrospinal fluid from patients with HAM/TSP. Ann Neurol. 2001; 50:807-812.
28. Siekevitz M, Feinberg MB, Holbrook N, Wong-Staal F, Greene WC. Activation of interleukin 2 and interleukin 2 receptor (Tac) promoter expression by the trans-activator (tat) gene product of human T-cell leukemia virus, type I. Proc Natl Acad Sci U S A. 1987;84:5389-5393.
29. Cross SL, Feinberg MB, Wolf JB, Holbrook NJ, Wong-Staal F, Leonard WJ. Regulation of the human interleukin-2 receptor alpha chain promoter: activation of a nonfunctional promoter by the transactivator gene of HTLV-I. Cell. 1987;49:47-56.
30. Azimi N, Brown K, Bamford RN, Tagaya Y, Siebenlist U, Waldmann TA. Human T cell lymphotropic virus type I Tax protein trans-activates interleukin 15 gene transcription through an NF-kappaB site. Proc Natl Acad Sci U S A. 1998;95: 2452-2457.
31. Mariner JM, Lantz V, Waldmann TA, Azimi N. Human T cell lymphotropic virus type I Tax activates IL-15R alpha gene expression through an NF-kappa B site. J Immunol. 2001;166:2602-2609.
32. Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol. 2006;6: 595-601.
33. Guidotti LG, Chisari FV To kill or to cure: options in host defense against viral infection. CurrOpin Immunol. 1996;8:478-483.
34. Trapani JA, Sutton VR, Smyth MJ. CTLgranules: evolution of vesicles essential for combating virus infections. Immunol Today. 1999;20:351-356.
35. Vine AM, Heaps AG, Kaftantzi L, et al. The role of CTLs in persistent viral infection: cytolytic gene expression in CD8+ lymphocytes distinguishes between individuals with a high or low proviral load of human T cell lymphotropic virus type 1. J Immunol. 2004;173:5121-5129.
36. Kannagi M, Shida H, Igarashi H, et al. Target epitope in the Tax protein of human T-cell leukemia virus type I recognized by class I major histocompatibility complex-restricted cytotoxic T cells. J Virol. 1992;66:2928-2933.
37. Greten TF, Slansky JE, Kubota R, et al. Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19-specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. Proc Natl Acad Sci USA. 1998;95:7568-7573.
38. Kubota R, Kawanishi T Matsubara H, Manns A, Jacobson S. Demonstration of human T lymphotropic virus type I (HTLV-I) tax-specific CD8+ lymphocytes directly in peripheral blood of HTLV-l-associated myelopathy/tropical spastic paraparesis patients by intracellular cytokine detection. J Immunol. 1998;161:482-488.
39. Barry M, Bleackley RC. CytotoxicTlymphocytes: all roads lead to death. Nat Rev Immunol. 2002;2: 401-409.
40. Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods. 2003;281:65-78.
41. Rubio V, Stuge TB, Singh N, et al. Ex vivo identification, isolation and analysis of tumor-cytolyticT cells. Nat Med. 2003;9:1377-1382.
42. Betts MR, Nason MC, West SM, etal. HIVnonprogressors preferentially maintain highly functional HIV-specificCD8+Tcells. Blood. 2006; 107:4781-4789.
43. KozakoT, ArimaN, Toji S, etal. Reduced frequency, diversity, and function of human T cell leukemia virus type 1-specific CD8+ T cell in adult T cell leukemia patients. J Immunol. 2006; 177:5718-5726.
44. Gehring AJ, Sun D, Kennedy PT, etal. The level of viral antigen presented by hepatocytes influences CD8 T-cell function. J Virol. 2007;81:2940-2949.
45. Betts MR, Price DA, Brenchley JM, et al. The functional profile of primary human antiviral CD8+ T cell effector activity is dictated by cognate peptide concentration. J Immunol. 2004;172: 6407-6417.
46. Koenig S, Woods RM, Brewah YA, et al. Characterization of MHCclass I restricted cytotoxicTcell responses to tax in HTLV-1 infected patients with neurologic disease. J Immunol. 1993;151:3874-3883.
47. den Haan JM, Bevan MJ. Antigen presentation to CD8+ T cells: cross-priming in infectious diseases. CurrOpin Immunol. 2001;13:437-441.
48. Hanon E, Hall S, Taylor GP, etal. Abundant tax protein expression in CD4+ T cells infected with human T-cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes. Blood. 2000;95:1386-1392.
49. Liu K, Catalfamo M, Li Y, Henkart PA. Weng NP. IL-15 mimics Tcell receptor crosslinking in the induction of cellular proliferation, gene expression, and cytotoxicity in CD8+ memory T cells. Proc Natl Acad Sci U SA. 2002;99:6192-6197.
50. Alves NL, Hooibrink B, Arosa FA, van Lier RA. IL-15 induces antigen-independent expansion and differentiation of human naive CD8+ T cells in vitro. Blood. 2003;102:2541-2546.
51. White L, Krishnan S, Strbo N, et al. Differential effects of IL-21 and IL-15 on perforin expression, lysosomal degranulation, and proliferation in CDS T cells of patients with human immunodeficiency virus-1 (HIV). Blood. 2007;109:3873-3880.
52. Tagaya Y, Bamford RN, DeFilippis AP, Waldmann TA. IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. Immunity. 1996;4: 329-336.
53. Dubois S, Mariner J, Waldmann TA, Tagaya Y IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity. 2002;17: 537-547.
54. Budagian V, Bulanova E, Orinska Z, et al. Reverse signaling through membrane-bound interleukin-15. J Biol Chem. 2004;279:42192-42201.
55. Neely GG, Epelman S, Ma LL, et al. Monocyte surface-bound IL-15 can function as an activating receptor and participate in reverse signaling. J Immunol. 2004;172:4225-4234.
56. Neely GG, Robbins SM, Arnankwah EK, etal. Lipopolysaccharide-stimulated or granulocytemacrophage colony-stimulating factor-stimulated monocytes rapidly express biologically active IL-15 on their cell surface independent of new protein synthesis. J Immunol. 2001;167:5011-5017.
57. Guex-CrosierY, Raber J, Chan CC, etal. Humanized antibodies against the alpha-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. J Immunol. 1997:158:452-458.
58. Faroudi M, Utzny C, Salio M, etal. Lytic versus stimulatory synapse in cytotoxic T lymphocyte/target cell interaction: manifestation of a dual activation threshold. Proc Natl Acad Sci U S A. 2003; 100:14145-14150.
59. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5:953-964.
60. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol. 2002;2:151-161.
61. Ploegh HL. Viral strategies of immune evasion. Science. 1998;280:248-253.
62. Johnson JM, Nicot C, Fullen J, etal. Free major histocompatibility complex class I heavy chain is preferentially targeted for degradation by human T-cell leukemia/lymphotropic virus type 1 p12(1) protein. J Virol. 2001;75:6086-6094.
63. DohertyTM, Seder RA, Sher A. Induction and regulation of IL-15 expression in murine macrophages. J Immunol. 1996;156:735-741.
64. Atedzoe BN, Ahmad A, Menezes J. Enhancement of natural killer cell cytotoxicity by the human herpesvirus-7 via IL-15 induction. J Immunol. 1997; 159:4966-4972.
65. Zhang X; Sun S, Hwang L Tough DF, Sprent J. Potent and selective stimulation of rnemoryphenotype CD8+ T cells in vivo by IL-15. Immunity. 1998;8:591-599.
66. Ogasawara K, Hida S, Azimi N, et al. Requirement tor IRF-1 in the microenvironment supporting development of natural killer cells. Nature. 1998:391:700-703.
67. Becker TC, Wherry EJ, Boone D, et al. Interleukin 15 is required tor proliferative renewal of virusspecific memory CD8 T cells. J Exp Med. 2002; 195:1541-1548.
68. Goldrath AW, Sivakumar PV, Glaccum M, et al. Cytokine requirements for acute and Basal homeostatic proliferation of naive and memory CD8+ T cells. J Exp Med. 2002;195:1515-1522.
69. Marcondes MC, Burdo TH, Sopper S, et al. Enrichment and persistence of virus-specific CTL in the brain of simian immunodeficiency virusinfected monkeys is associated with a unique cytokine environment. J Immunol. 2007;178:5812-5819.
70. Azimi N, Jacobson S, Leist T, Waldmann TA. Involvement of IL-15 in the pathogenesis of human Tlymphotropic virus type l-associated myelopathy/tropical spastic paraparesis: implications for therapy with a monoclonal antibody directed to the IL-2/15R beta receptor. J Immunol. 1999;163: 4064-4072.
71. Ahuja J, Kampani K, Datta S, Wigdahl B, Flaig KE; Jain P. Use of human antigen presenting cell gene array profiling to examine the effect of human T-cell leukemia virus type 1 Tax on primary human dendritic cells. J Neurovirol. 2006; 12:47-59.
72. Azimi N. Nagai M, Jacobson S. Waldmann TA. IL-15 plays a major role in the persistence of Tax-specific CD8 cells in HAM/TSP patients. Proc Natl Acad Sci U S A. 2001;98:14559-14564.
73. Abe M, Umehara F, Kubota R, Moritoyo T Izumo S. Osame M. Activation of macrophages/microglia with the calcium-binding proteins MRP14 and MRP8 is related to the lesional activities in the spinal cord of HTLV-I associated myelopathy. J Neurol. 1999;246:358-364.